New York State Department of Health

FTC Staff Opposes Proposed Certificate of Public Advantage That Could Shield SUNY Upstate Medical University’s Acquisition of Crouse Health System from Antitrust Scrutiny

Retrieved on: 
Monday, October 31, 2022
Comment, New York State Department of Health, Commission, Depression, Federal Trade Commission, Nursing, COPA, Policy, Patient, State University of New York Upstate Medical University, News, Agriopas, Research, Crouse, Growth, Public, FTC, Health insurance, Facebook

SUNY Upstate Medical University and Crouse Health System announced the proposed merger in April 2022, then filed a COPA application in July.

Key Points: 
  • SUNY Upstate Medical University and Crouse Health System announced the proposed merger in April 2022, then filed a COPA application in July.
  • The New York State Department of Health has invited public comments on the application.
  • Moreover, the proposed merger between SUNY Upstate and Crouse would reduce the number of hospital options available for nearly all patients in Onondaga County from three to two.
  • FTC staff submitted a public version and non-public version of its comment, with claimed confidential material redacted from the public version.

OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update

Retrieved on: 
Thursday, October 27, 2022
NGS, Infection, Securities Exchange Act of 1934, Security (finance), U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Nasdaq, New York State Department of Health, UZ Leuven, Goal, Hospital, NMPA, Adoption, ARES, Streptococcus pneumoniae, Technology, Nadine Opgen-Rhein, European Investment Bank, COVID-19, GLOBE, Precision medicine, Curetis, Securities Act of 1933, Genetics, Solution, Pharmaceutical industry, MD

Cash as of September 30, 2022 was approximately $10.3 million and, following the successful closing of a financing transaction, was approximately $13.3 million as of October 3, 2022.

Key Points: 
  • Cash as of September 30, 2022 was approximately $10.3 million and, following the successful closing of a financing transaction, was approximately $13.3 million as of October 3, 2022.
  • OpGen, Inc. (Rockville, MD, U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease.
  • This press release includes statements regarding OpGens third quarter 2022 results and the current business of OpGen.
  • We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, October 14, 2022
Conference, STI, Hepatitis, FX, Chlamydia, CEO, Operating cost, Public expenditure, DNA, Syphilis, CDC, Biochemistry, New York State Department of Health, Severe acute respiratory syndrome coronavirus 2, DOH, NYSE, Jefferies Group, General counsel, GAAP, Investment, SG, NEW, Center, Company, Industry, Conference call, GLOBE, HPV, FDA, APOE, Growth, Review, COVID-19 testing, Laboratory, Income, EUA, Simplex, Goal, ECL, EBITDA, Internet, Rheumatology, EDX, ENZ, Total, GMP, LDT, Monkeypox, Health, Â, Research, Gonorrhea, ELS, COVID-19, Pharmaceutical industry, Management, Video game, Fine chemical, Vaccine, Reinsurance, Fossil fuel, Enzo, COVID

Enzo Life Sciences fiscal 2022 revenues amounted to $32.6 million, up 6% from fiscal 2021, or 8% on an FX adjusted basis.

Key Points: 
  • Enzo Life Sciences fiscal 2022 revenues amounted to $32.6 million, up 6% from fiscal 2021, or 8% on an FX adjusted basis.
  • Total fourth quarter 2022 revenues were $20.3 million, compared to $24.8 million in the fourth quarter 2021.
  • Consolidated gross margins were 21.4% in the fiscal fourth quarter as compared to 39.5% for the comparable quarter in the previous fiscal year.
  • Enzo Clinical Lab revenue was $12.4 million in the fiscal fourth quarter as compared to $16.8 million in the fourth quarter of 2021.

Applied DNA Announces Receipt of Largest Single Purchase Order for LinearDNA™ To-Date

Retrieved on: 
Monday, October 10, 2022
Health, Stem Cells, Genetics, Research, Science, Pharmaceutical, Biotechnology, NYSDOH, Lists of diseases, LinkedIn, Drug Quality and Security Act, SEC, New York State Department of Health, Diagnosis, Annual report, NASDAQ, Biotechnology, RNA, Twitter, Research, Applied DNA Sciences, IVT, Securities Act of 1933, History, PCR, Private Securities Litigation Reform Act, Infection, Company, Cancer, Industry, CEO, Securities Exchange Act of 1934, Bacteria, Forward-looking statement, DNA, FDA, Vaccine, Applied Food Technologies

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company), a leader in PCR-based DNA technologies, announced today that it received its largest single purchase order for LinearDNA valued above the mid-six-figures.

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company), a leader in PCR-based DNA technologies, announced today that it received its largest single purchase order for LinearDNA valued above the mid-six-figures.
  • LinearDNA is produced using an enzymatic (cell-free) manufacturing platform that eliminates the use of fermenters and bacteria required by plasmid DNA, the industrys current manufacturing standard for DNA.
  • LinearDNA eliminates many of the challenges associated with current plasmid-based DNA manufacturing and produces a DNA product without the risks of bacterial contamination and non-target DNA sequences.
  • Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (DNA).

Eriksen Translations Wins 2022 WBEC Metro NY Access New York City and State Awards

Retrieved on: 
Monday, October 10, 2022
Civic, Port, Health, WBE, Transcreation, Mayor's Office of Immigrant Affairs, The Developmental Disabilities Assistance and Bill of Rights Act of 2000, New York State Department of Health, Public sector, Housing, WBES, Employment, Breakfast, Education, New Yorkers, Translation, National Language Service Corps, Czech State Award for Translation, Port Authority of New York and New Jersey, Environmental protection, Done Deal, WBEC, English as a second or foreign language, CEO, Metro New York, Museum, City, Leadership, Restaurant

BROOKLYN, N.Y., Oct. 10, 2022 /PRNewswire-PRWeb/ -- Eriksen Translations Inc. (http://www.eriksen.com), a leading Language Services Provider, received the WBEC Metro NY Done Deals Access New York City Award and Access New York State Award at the Women's Business Enterprise Council (WBEC) Metro New York Annual Breakthrough Breakfast on October 7. The awards honor the Women Business Enterprise (WBE) that reported the most Done Deals with the City and State of New York during the challenge period.

Key Points: 
  • The Women's Business Enterprise Council (WBEC) Metro New York has awarded Language Services Provider Eriksen Translations its Access New York City and State Awards at the organization's Annual Breakthrough Breakfast.
  • BROOKLYN, N.Y., Oct. 10, 2022 /PRNewswire-PRWeb/ -- Eriksen Translations Inc. ( http://www.eriksen.com ), a leading Language Services Provider, received the WBEC Metro NY Done Deals Access New York City Award and Access New York State Award at the Women's Business Enterprise Council (WBEC) Metro New York Annual Breakthrough Breakfast on October 7.
  • Eriksen Translations provides language services to help New York City and State agencies make public services and programs accessible to people with Limited English Proficiency.
  • "I am honored to have received this award from WBEC New York and grateful for our ongoing partnerships with New York City and State agencies," said Vigdis Eriksen, Founder and CEO.

NACDD Announces New Board of Directors

Retrieved on: 
Friday, September 30, 2022
Linda, Arizona Department, MPH, Arkansas Department of Health, MPA, Department, New York State Department of Health, MHS, Center, Control, Large, Division, Bureau, Doctor of Public Health, Rhode Island Department of Health, Minnesota Department of Health, Maryland Department of Health, Michigan Department of Health and Human Services, Community health worker, Health Promotion International, Nebraska Department of Health & Human Services, Maryland Department of Natural Resources, Arizona Department of Health Services, Human services, Public health, National, Texas Department of State Health Services, Integrated Opisthorchiasis Control Program, Director, Association for Community Health Improvement, Board, Ministry of Social Affairs, Chronic condition, National Association, FAAFP, Health care, Renewable energy, Hospital, MD, State

ATLANTA, Sept. 30, 2022 /PRNewswire/ -- The National Association of Chronic Disease Directors (NACDD) is pleased to introducetwo new officers and seven incoming Board Members for its Fiscal Year 2022-2023.

Key Points: 
  • ATLANTA, Sept. 30, 2022 /PRNewswire/ -- The National Association of Chronic Disease Directors (NACDD) is pleased to introducetwo new officers and seven incoming Board Members for its Fiscal Year 2022-2023.
  • Pier has worked extensively in public health for more than 20 years.
  • Simon is the Deputy Chief Medical Officer and State Chronic Disease Director at the Arkansas Department of Health and was the immediate past Treasurer of the Board.
  • The following new Board Members will serve as At Large Directors with their term beginning Oct. 1 and continuing through Sept. 30, 2024.

Rheonix COVID-19™ MDx Assay Receives Expanded FDA Emergency Use Authorization to Include Saliva Home Collection Kit

Retrieved on: 
Monday, September 19, 2022
Research, General Health, Pharmaceutical, Oncology, Infectious Diseases, Clinical Trials, Science, COVID-19, Biotechnology, Medical Supplies, FDA, Health, Other Science, Adult, EUA, Act, Laboratory, COVID-19, Saliva, STI, FDA, LLC, Virus, Inc., Severe acute respiratory syndrome coronavirus 2, Organization, Beer, COVID, CEO, Emergency Use Authorization, Male, Diagnosis, New York State Department of Health, Board, RT, Research, Urine, COVID-19 testing, PCR, Pharmaceutical industry, Vaccine, Listeria

announced today that the United States Food and Drug Administration (FDA) has issued an expanded Emergency Use Authorization (EUA) for the Rheonix COVID-19 MDx Assay to include home collection using the Rheonix Laboratories COVID-19 PCR Test Saliva Home Collection Kit.

Key Points: 
  • announced today that the United States Food and Drug Administration (FDA) has issued an expanded Emergency Use Authorization (EUA) for the Rheonix COVID-19 MDx Assay to include home collection using the Rheonix Laboratories COVID-19 PCR Test Saliva Home Collection Kit.
  • Initially, the Rheonix COVID-19 saliva home collection kit will be made available for use through Rheonix Laboratories, LLC, a New York State-permitted CLIA-compliant clinical laboratory located in Ithaca, New York.
  • Rheonix plans to expand use of the home collection kit through partnerships with additional authorized laboratories.
  • Rheonixs clinical assays include the Rheonix COVID-19 MDx Assay for use under FDA emergency use authorization and the STI TriPlex Assay for the detection of sexually transmitted infections in male urine.

Yuvo Health Partners With Primary Care Development Corporation (PCDC) To Expand and Support Primary Care Access in Marginalized Communities

Retrieved on: 
Wednesday, September 14, 2022
Health, Efficiency, Policy, FQHC, CDFI, Community development financial institution, Association, Partnership, Capacity building, Community, Health equity, Program, Medicaid, CEO, Federally Qualified Health Center, Community development, New York State Department of Health, Research, PCDC, Fidelis Care, VBP, IPA, BIPOC, Health insurance, Medicine

"We're pleased to partner with Yuvo Health, which shares our deep commitment to both FQHCs and expanding investment in primary care, overall."

Key Points: 
  • "We're pleased to partner with Yuvo Health, which shares our deep commitment to both FQHCs and expanding investment in primary care, overall."
  • In May 2022, Yuvo Health announced four FQHCs that joined the company's independent provider association (IPA): Long Island Select Healthcare, Metro Community Health Centers, Joseph P. Addabbo Family Health Center, and Advantage Care Health Centers.
  • Founded in 1993, the Primary Care Development Corporation (PCDC) is a Community Development Financial Institution and nationally recognized nonprofit organization dedicated to expanding access to quality primary care, in order to improve the health of families and communities, lessen disparities, and reduce health care costs.
  • To date, PCDC has helped over 3,000 primary care practices improve delivery of care and leveraged over $1.3 billion in capital to enhance capacity in disinvested communities.

MTX Group Deploys Monkeypox Vaccine Solution as Case Counts Surge Across the Country

Retrieved on: 
Friday, September 9, 2022
COVID-19, Monkeypox, Public health, Decision-making, New York State Department of Health, View, Solution, Coronavirus, Ancaster Senior Public School, Organization, Public sector, Multimedia, Information, Happiness, Health, MTX, Government, Disease surveillance, Vaccine, Pharmaceutical industry

DALLAS, Sept. 9, 2022 /PRNewswire/ -- As the number of confirmed Monkeypox cases in the United States nears 19,000, state and local governments are responding to yet another public health crisis.

Key Points: 
  • To address this challenge and others, MTX Group, Inc. (MTX) has adapted our groundbreaking COVID-19 disease surveillance and vaccine management solutions to help state and local health departments respond to future threats to public health.
  • These MTX solutions utilize data to monitor infections and facilitate better decision making for communities gearing up to fight the fast-spreading Monkeypox virus.
  • MTX converted its COVID-19 response systems into MTX Monkeypox Surveillance and Vaccine Management systems to help health departments collect and manage valuable data to monitor infections and exposed individuals, allocate and deliver vaccines and make informed decisions to manage public health.
  • MTX invites Public Health Officials to attend our upcoming Disease Surveillance and Monkeypox Live Webinar on Tuesday, September 20, 2022 at 3:00 PM EST.

Applied DNA Launches Monkeypox Testing Service

Retrieved on: 
Tuesday, September 6, 2022
Managed Care, Research, General Health, Pharmaceutical, Infectious Diseases, Hospitals, Genetics, Science, Biotechnology, Medical Supplies, Practice Management, Health, Other Science, COVID-19, CEO, Securities Exchange Act of 1934, Securities Act of 1933, Research, Applied DNA Sciences, Monkeypox virus, CLEP, NASDAQ, Laboratory developed test, New York State Department of Health, LinkedIn, DNA, SEC, Infection, PCR, Monkeypox, LDT, FDA, Biotechnology, History, Attention, Certification, LLC, Twitter, NYSDOH, Annual report, Private Securities Litigation Reform Act, TAT, CDC, Forward-looking statement, Vaccine, Applied Food Technologies

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has launched monkeypox testing as a clinical reference laboratory testing service available to hospital systems and clinical labs located in New York State and in states that recognize New York's CLEP/CLIA certification for testing.

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has launched monkeypox testing as a clinical reference laboratory testing service available to hospital systems and clinical labs located in New York State and in states that recognize New York's CLEP/CLIA certification for testing.
  • Having built ADCLs stellar reputation for high-capacity, PCR-based COVID-19 testing with rapid TAT, we believe we can bring to bear the same expertise to the monkeypox public health emergency, stated Dr. James A. Hayward, president and CEO of Applied DNA Sciences.
  • ADCLs monkeypox test utilizes an A17L gene-target specific to monkeypox virus Clade II that enables the qualitative detection and differentiation of the monkeypox virus from other non-variola orthopoxviruses using real-time PCR.
  • To learn more about ADCLs monkeypox testing service, click to: adnas.com/monkeypox-testing
    Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (DNA).